Table 1.
Baseline characteristics of TD-NSAA.
| Projects | Progressive group (n=57) | Non-progressive group (n=67) | Statistic | P value |
|---|---|---|---|---|
| Age (Median) | 32 (3~80) | 32 (7~80) | t=0.190 | 0.346 |
| Disease course (Median) | 64 (8~362) | 32 (3~363) | t=-1.970 | 0.1 |
| Gender (Male/Female) | 28/29 | 38/29 | χ2 = 0.713 | 0.398 |
| ANC (×109/L, median) | 0.82 (0.05~7.85) | 1.15 (0.24~3.26) | t=1.884 | 0.06 |
| ALC (×109/L, median) | 1.11 (0.36-3.93) | 1.51 (0.18~4.18) | t=0.998 | 0.036 |
| ARC (×109/L, median) | 24.92 (3.81~134.8) | 45.1 (3.7~379.2) | t=2.757 | 0.7 |
| BPC (×109/L, median) | 13 (1~102) | 17 (2~177) | t=1.764 | 0.04 |
| Complications | ||||
| Liver and kidney dysfunction | 20 (35.1%) | 22 (32.8%) | χ2 = 0.070 | 0.792 |
| Gingival hyperplasia | 0 (0%) | 6 (8.9%) | χ2 = 5.346 | 0.006 |
| Anemic heart disease | 9 (15.7%) | 3 (4.5%) | χ2 = 4.509 | 0.012 |
| Hypertension | 3 (5.2%) | 4 (5.9%) | χ2 = 0.029 | 0.865 |
| Diabetes or impaired glucose. tolerance | 17 (29.8%) | 7 (10.4%) | χ2 = 7.408 | 0.006 |
| Iron overload | 37 (64.9) | 16 (23.9%) | χ2 = 21.187 | 0.001 |
| Severe infection | 22 (38.6%) | 7 (10.4%) | χ2 = 13.620 | 0 |
| Oral ulcer or herpes | 3 (5.2%) | 2 (3.0%) | χ2 = 0.413 | 0.52 |
| Viral hepatitis | 17 (29.8%) | 21 (31.3%) | χ2 = 0.033 | 0.855 |
| Death | 7 (12.2%) | 3 (4.5%) | χ2 = 2.529 | 0.112 |
| MDS/AML | 1 (1.7%) | 2 (3.0%) | χ2 = 0.198 | 0.657 |
| PNH | 4 (7.0%) | 7 (10.4%) | χ2 = 0.488 | 0.503 |
ANC, absolute neutrophil count; ALC, absolute lymphocyte count; ARC, absolute reticulocyte count; BPC, blood platelet count; MDS, myelodysplastic syndrome; AML, acute myeloid leukocyte; PNH, paroxysmal nocturnal hemoglobinuria.